Liminal BioSciences Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05349435
- Locations
- 🇬🇧
Celerion, Belfast, Northern Ireland, United Kingdom
A Healthy Volunteer Study of PBI-4050
Phase 1
Completed
- Conditions
- FibrosisInflammation
- Interventions
- Drug: PBI-4050/ Placebo
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT04695041
- Locations
- 🇬🇧
Covance CRU, Ltd., Leeds, United Kingdom
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04068259
- Locations
- 🇨🇦
Syneos Health, Québec, Canada
Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT03637049
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03184584
- Locations
- 🇬🇧
University Hospitals Birmingham NHS Foundation Trus, Birmingham, United Kingdom
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
Phase 2
Terminated
- Conditions
- Type 2 Diabetes MellitusMetabolic Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT03081598
- Locations
- 🇨🇦
Omnispec Clinical Research, Mirabel, Quebec, Canada
🇨🇦C-Health, Edmonton, Alberta, Canada
🇨🇦LMC Clinical Research Inc., Montréal, Canada
Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT02955888
- Locations
- 🇨🇦
Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval (IUCPQ), Quebec, Canada
🇨🇦St. Paul's Hospital - Pacific Lung Health Centre (PLHC), Vancouver, British Columbia, Canada
🇨🇦Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada
Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02739217
- Locations
- 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02562573
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Liminal BioSciences Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT02538536
© Copyright 2025. All Rights Reserved by MedPath